+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antifibrinolytic Drugs Market by Indication and End user: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • ID: 4990107
  • Report
  • December 2019
  • Region: Global
  • 165 pages
  • Allied Analytics LLP
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Acic Fine Chems
  • Akorn
  • Amerigen Pharms Ltd
  • Aurobindo Pharma Ltd.
  • Mylan
  • Pfizer (GenMed)
  • MORE
The global antifibrinolytic drugs market was valued at $1,3593 million in 2018 and is expected to reach $1,9333 million by 2026, registering a CAGR of 4.5% from 2019 to 2026. Antifibrinolytic is a type of drug that helps in the formation of blood clot. These drugs prevent the breakdown of fibrin, which is the main protein involved in blood clotting. These drugs can be used to prevent serious bleeding in patients suffering from life threatening conditions such as hemophilia, very heavy menstrual bleeding, or some types of vascular tumors. They are also widely used to prevent or control bleeding during or after a surgery or after a traumatic injury. An increase in usage of these drugs has been witnessed since past few years, owing to their increased applications.

Rise in medical a surgeries including dental and cardiac, accidental trauma, and increase in incidence of angioedema across the globe are the major factors that drive the antifibrinolytic drugs market growth. Antifibrinolytic drugs play a crucial role in the prevention of clot lysis and blood loss. Considerable a surge in prevalence of bleeding disorders propels the antifibrinolytic drugs market growth. However, high cost of these drugs hamper the market growth. Furthermore, increase in research & development for developing novel innovative antifibrinolytic drugs is anticipated to create new opportunities for the market.

The market is segmented on the basis of indication, end-users, and region. On the basis of indication, it is classified into gynecology, hereditary angiedema, fibrinolytic response testing, a surgeries, and others. By end user, it is divided into hospitals & clinics, ambulatory surgical centers, and healthcare specialty process. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
  • Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS

By Indication
  • Gynecology
  • Hereditary Angiedema
  • Fibrinolytic Response Testing
  • a surgeries
  • Others
By End User
  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Trauma Centers
By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
Key Players
  • Acic Fine Chems
  • Xanodyne Pharmaceuticals
  • Aurobindo Pharma Ltd
  • Akorn
  • Mylan N.V.
  • Pfizer (GenMed)
  • Sanofi SA
  • Zydus Cadila
  • Takeda
  • Amerigen Pharms Ltd
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acic Fine Chems
  • Akorn
  • Amerigen Pharms Ltd
  • Aurobindo Pharma Ltd.
  • Mylan
  • Pfizer (GenMed)
  • MORE
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. CXO Perspective

Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.3. Porter’S Five Forces Analysis
3.3.1. Moderate Bargaining Power of Buyers
3.3.2. Low Bargaining Power of Suppliers
3.3.3. Moderate Threat of Substitutes
3.3.4. Low Threat of New Entrants
3.3.5. Moderate Competitive Rivalry
3.4. Top Player Positioning
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. Surge In Severe Road Accidents
3.5.1.2. Significant Increase In Surgical Procedures
3.5.2. Restraint
3.5.2.1. High Cost of These Drugs
3.5.3. Opportunity
3.5.3.1. Various Growth Opportunities In Emerging Economies

Chapter 4: Antifibrinolytic Drugs Market, By Indication
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Gynecology
4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast
4.2.3. Market Share Analysis, By Country
4.3. Hereditary Angioedema
4.3.1. Key Market Trends And Growth Opportunities
4.3.2. Market Size And Forecast
4.3.3. Market Share Analysis, By Country
4.4. Fibrinolytic Response Testing
4.4.1. Key Market Trends And Opportunities
4.4.2. Market Size And Forecast
4.4.3. Market Share Analysis, By Country
4.5. Surgeries
4.5.1. Key Market Trends And Opportunities
4.5.2. Market Size And Forecast
4.5.3. Market Share Analysis, By Country
4.6. Others
4.6.1. Key Market Trends And Opportunities
4.6.2. Market Size And Forecast
4.6.3. Market Share Analysis, By Country

Chapter 5: Antifibrinolytic Drugs Market, By End User
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Hospitals
5.2.1. Market Size And Forecast
5.2.2. Market Share Analysis, By Country
5.3. Ambulatory Surgery Centers
5.3.1. Market Size And Forecast
5.3.2. Market Share Analysis, By Country
5.4. Trauma Centers
5.4.1. Market Size And Forecast
5.4.2. Market Share Analysis, By Country

Chapter 6: Antifibrinolytic Drugs Market, By Region
6.1. Overview
6.1.1. Market Size And Forecast
6.2. North America
6.2.1. Key Market Trends And Opportunities
6.2.2. Market Size And Forecast, By Country
6.2.3. Market Size And Forecast, By Indication
6.2.4. Market Size And Forecast, By End User
6.2.5. U.S.
6.2.5.1. U.S. Market Size And Forecast, By Indication
6.2.5.2. U.S. Market Size And Forecast, By End User
6.2.6. Canada
6.2.6.1. Canada Market Size And Forecast, By Indication
6.2.6.2. Canada Market Size And Forecast, By End User
6.2.7. Mexico
6.2.7.1. Mexico Market Size And Forecast, By Indication
6.2.7.2. Mexico Market Size And Forecast, By End User
6.3. Europe
6.3.1. Key Growth Factors And Opportunities
6.3.2. Market Size And Forecast, By Country
6.3.3. Market Size And Forecast, By Indication
6.3.4. Market Size And Forecast, By End User
6.3.5. Germany
6.3.5.1. Germany Market Size And Forecast, By Indication
6.3.5.2. Germany Market Size And Forecast, By End User
6.3.6. France
6.3.6.1. France Market Size And Forecast, By Indication
6.3.6.2. France Market Size And Forecast, By End User
6.3.7. UK
6.3.7.1. UK Market Size And Forecast, By Indication
6.3.7.2. UK Market Size And Forecast, By End User
6.3.8. Italy
6.3.8.1. Italy Market Size And Forecast, By Indication
6.3.8.2. Italy Market Size And Forecast, By End User
6.3.9. Rest of Europe
6.3.9.1. Rest of Europe Market Size And Forecast, By Indication
6.3.9.2. Rest of Europe Market Size And Forecast, By End User
6.4. Asia-Pacific
6.4.1. Key Growth Factors And Opportunities.
6.4.2. Market Size And Forecast, By Country
6.4.3. Market Size And Forecast, By Indication
6.4.4. Market Size And Forecast, By End User
6.4.5. Japan
6.4.5.1. Japan Market Size And Forecast, By Indication
6.4.5.2. Japan Market Size And Forecast, By End User
6.4.6. China
6.4.6.1. China Market Size And Forecast, By Indication
6.4.6.2. China Market Size And Forecast, By End User
6.4.7. India
6.4.7.1. India Market Size And Forecast, By Indication
6.4.7.2. India Market Size And Forecast, By End User
6.4.8. Rest of Asia-Pacific
6.4.8.1. Rest of Asia-Pacific Market Size And Forecast, By Indication
6.4.8.2. Rest of Asia - Pacific Market Size And Forecast, By End User
6.5. LAMEA
6.5.1. Key Growth Factors And Opportunities
6.5.2. Market Size And Forecast, By Country
6.5.3. Market Size And Forecast, By Indication
6.5.4. Market Size And Forecast, By End User
6.5.5. Brazil
6.5.5.1. Brazil Market Size And Forecast, By Indication
6.5.5.2. Brazil Market Size And Forecast, By End User
6.5.6. Saudi Arabia
6.5.6.1. Saudi Arabia Market Size And Forecast, By Indication
6.5.6.2. Saudi Arabia Market Size And Forecast, By End User
6.5.7. South Africa
6.5.7.1. South Africa Market Size And Forecast, By Indication
6.5.7.2. South Africa Market Size And Forecast, By End User
6.5.8. Rest of LAMEA
6.5.8.1. Rest of LAMEA Market Size And Forecast, By Indication
6.5.8.2. Rest of LAMEA Market Size And Forecast, By End User

Chapter 7: Company Profiles
7.1. Akorn Inc.
7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance
7.2. Aurobindo Pharma Limited
7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Operating Business Segments
7.2.4. Product Portfolio
7.2.5. Business Performance
7.3. Bayer Ag
7.3.1. Company Overview
7.3.2. Company Snapshot
7.3.3. Operating Business Segments
7.3.4. Product Portfolio
7.3.5. Business Performance
7.4. Ferring Holding Sa
7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Operating Business Segments
7.4.4. Product Portfolio
7.4.5. Business Performance
7.5. Mylan N.V.
7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance
7.6. Novartis International Ag (Sandoz)
7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance
7.7. Pfizer Inc.
7.7.1. Company Overview
7.7.2. Company Snapshot
7.7.3. Operating Business Segments
7.7.4. Product Portfolio
7.7.5. Business Performance
7.8. Sanofi S.A.
7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.8.5. Business Performance
7.9. Takeda Pharmaceutical Company Limited
7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio
7.9.5. Business Performance
7.10. Vitruvias Therapeutics Inc.
7.10.1. Company Overview
7.10.2. Company Snapshot
7.10.3. Operating Business Segments
7.10.4. Product Portfolio
7.10.5. Business Performance
7.10.1. Key Strategic Moves And Developments
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Acic Fine Chems
  • Akorn
  • Amerigen Pharms Ltd
  • Aurobindo Pharma Ltd.
  • Mylan
  • Pfizer (GenMed)
  • MORE
According to the report titled, 'Antifibrinolytic Drugs Market by Indication and End User: Global opportunity analysis and industry forecast, 2019-2026', the global antifibrinolytic drugs market size is expected to reach $1,9333 million by 2026, registering a CAGR of 4.5% from 2019 to 2026, in terms of value.

Antifibrinolytic is the class of drugs that is widely used to inhibit fibrinolysis by stopping activation of the proenzyme plasminogen to plasmin. This intrusion is crucial for averting clot degradation in areas rich in the fibrinolysis prone areas such as oral cavity, nasal cavity, and female reproductive tract. Approved antifibrinolytic drugs include Epsilon aminocaproic acid, Tranexamic acid, Amicar, aminocaproic acid, aprotinin, and Cyklokapron. In addition, these drugs find their application in a surgeries such as cardiovascular a surgeries, neuroa surgeries, and dental a surgeries. Furthermore, antifibrinolytic drugs are used by women to control heavy menstrual flow.

Considerable increase in road accidents, rise in medical a surgeries including cardiac, and dental, and a surge in prevalence of angioedema are the major factors that drive the antifibrinolytic drugs market growth. Antifibrinolytic drugs play a vital role in averting clot lysis and thereby, blood loss.

The antifibrinolytic drugs market is segmented on the basis of indication, end-users, and region. On the basis of indication, it is classified into gynecology, hereditary angiedema, fibrinolytic response testing, a surgeries, and others. By end user, it is divided into hospitals & clinics, ambulatory surgical centers, and healthcare specialty process. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

By type, the gynaecology segment accounted for majority of the market share in 2018 and is expected to exhibit a prominent growth rate in the near future, owing to the increased adoption of these drugs to prevent menorrhagia i.e. heavy menstrual flow. Further, these drugs are manufactured to reduce bleeding by inhibiting endometrial clot-dissolving enzymes in the uterine lining. Tranexamic acid (TXA) is the most widely used drug for controlling menorrhagia.

By end user, the hospitals & clinics segment dominated the antifibrinolytic drugs market in 2018 and is anticipated to maintain its dominance during the forecast period. This is attributed to the increased usage of these drugs in hospitals as most of the a surgeries such as cardiovascular and neuroa surgeries are performed in hospitals.

North America accounted for most of the Antifibrinolytics Drug Market share in 2018, and is anticipated to continue this trend during the forecast period. This is attributed to the increased adoption of these drugs by women to control heavy menstrual flow. Moreover, significant a surge in a surgeries in this region propels the market growth. However, the Asia-Pacific region is anticipated to grow at the fastest rate due to a surge in road accidents and increased usage of these drugs by women to control heavy menstrual flow.

Key Findings of the Study::

By indication, the gynecology segment accounted for the highest Antifibrinolytics Drug Market share of 28% in 2018, and is anticipated to grow at the fastest rate during the forecast period.
By region, North America was the major shareholder and accounted for the highest share of 42% in 2018.
Asia-Pacific is expected to grow at a CAGR of 6.1% during the forecast period.
By end user, the hospital & clinics segment dominated the market in 2018 and is anticipated to maintain its dominance during the forecast period.
Comprehensive competitive analysis and profiles of major market players such as Acic Fine Chems, Xanodyne Pharmaceuticals, Aurobindo Pharma Ltd., Akorn, Amerigen Pharms Ltd, Mylan, Pfizer (GenMed), Sanofi, Zydus Cadila and Takeda are provided in this report.
Note: Product cover images may vary from those shown
5 of 5
  • Acic Fine Chems
  • Xanodyne Pharmaceuticals
  • Aurobindo Pharma Ltd.
  • Akorn
  • Amerigen Pharms Ltd
  • Mylan
  • Pfizer (GenMed)
  • Sanofi
  • Zydus Cadila
  • Takeda
Note: Product cover images may vary from those shown
6 of 5

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll